Relay Therapeutics Begins Phase 3 Trial of Zovegalisib, Triggering Milestone for X-Chem DEL Collaboration
核心洞察
Relay Therapeutics has initiated a Phase 3 clinical trial of zovegalisib (搜索) (RLY-2608), a PI3K alpha (搜索) inhibitor that originated from an X-Chem (搜索) DNA-encoded chemical library screen.
The milestone falls under the companies' Research Collaboration and License Agreement, under which Relay licensed the inhibitor discovered through X-Chem (搜索)'s DEL platform.
The compound showed differentiated pharmacology, mutant selectivity and a novel allosteric binding site, and X-Chem (搜索)'s CEO said it could support a new treatment for breast cancer (搜索) patients.
Relay Therapeutics has initiated a Phase 3 clinical trial of zovegalisib (搜索) (RLY-2608), a drug candidate that began as a compound identified through a DNA-encoded chemical library (DEL) screen run by X-Chem (搜索). The start of the trial constitutes a milestone under the two companies' Research Collaboration and License Agreement, X-Chem announced on Sept. 22, 2026.
Zovegalisib (搜索) is an inhibitor of phosphoinositide 3-kinase alpha (PI3K alpha (搜索)), an oncology target. Relay licensed the inhibitor after it emerged from an X-Chem (搜索) DEL screen. According to X-Chem, the molecule demonstrated differentiated pharmacology, mutant selectivity and a novel allosteric binding site, and it served as the starting point for Relay's development of zovegalisib, which is currently in clinical testing.
Collaboration terms and compound origins
Under the Research Collaboration and License Agreement, the initiation of the Phase 3 trial triggers a milestone payment to X-Chem (搜索). X-Chem did not disclose the financial terms of the milestone or details of the Phase 3 trial design, including endpoints, patient population or dosing.
"The unique selectivity and binding site of RLY-2608 are a testament to the power of the X-Chem (搜索) DEL platform to discover unique chemical matter with differentiated pharmacology," said X-Chem chief executive Karen Lackey. "We are thrilled that our discovery platforms helped provide a starting point for a potential new treatment for patients with breast cancer (搜索)."
Relay chief executive Sanjiv Patel pointed to the discovery work behind the program. "X-Chem (搜索)'s excellence in DEL technology was apparent from the very beginning of this exciting project, and we are pleased to continue to advance the clinical development of zovegalisib (搜索) in patients with PI3K alpha (搜索)-driven diseases," he said.
Platform context
X-Chem (搜索) positions itself as a pioneer and global leader in DEL technology, combining computational science, discovery chemistry and data-driven insight to help biopharma partners identify differentiated hits, accelerate lead progression and advance complex programs. The company states that its platforms are intended to help partners find chemical matter with properties that distinguish it from compounds identified through other screening approaches.
The zovegalisib (搜索) program is the second stage of a discovery-to-clinic path that began with a screening campaign rather than with a known chemical series. Relay has not disclosed the specific breast cancer (搜索) setting or the comparator for the Phase 3 study.